Embecta (EMBC) Competitors $10.47 -0.26 (-2.42%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$10.46 -0.01 (-0.05%) As of 07/11/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, and LQDAShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Artivion Cadre Tandem Diabetes Care Establishment Labs Liquidia Technologies Embecta (NASDAQ:EMBC) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk. Which has higher valuation and earnings, EMBC or NVCR? Embecta has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmbecta$1.12B0.54$78.30M$0.9011.63NovoCure$605.22M3.24-$168.63M-$1.51-11.66 Do insiders and institutionals hold more shares of EMBC or NVCR? 93.8% of Embecta shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 0.4% of Embecta shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to EMBC or NVCR? In the previous week, NovoCure had 2 more articles in the media than Embecta. MarketBeat recorded 5 mentions for NovoCure and 3 mentions for Embecta. Embecta's average media sentiment score of 1.49 beat NovoCure's score of 0.57 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, EMBC or NVCR? Embecta has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Is EMBC or NVCR more profitable? Embecta has a net margin of 4.89% compared to NovoCure's net margin of -26.41%. Embecta's return on equity of -19.67% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets Embecta4.89% -19.67% 12.27% NovoCure -26.41%-45.46%-13.34% Do analysts prefer EMBC or NVCR? Embecta currently has a consensus target price of $19.33, indicating a potential upside of 84.65%. NovoCure has a consensus target price of $32.43, indicating a potential upside of 84.25%. Given Embecta's higher possible upside, equities analysts plainly believe Embecta is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33NovoCure 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryEmbecta beats NovoCure on 11 of the 16 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$627.09M$7.31B$5.60B$9.11BDividend Yield5.59%2.81%5.24%4.02%P/E Ratio11.6333.1327.9620.25Price / Sales0.5435.55430.8999.65Price / Cash3.2223.3737.4658.16Price / Book-0.826.858.045.49Net Income$78.30M$230.16M$3.18B$250.27M7 Day Performance1.45%0.01%3.63%4.75%1 Month Performance4.28%0.25%4.04%7.64%1 Year Performance-20.50%33.80%29.55%16.34% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.7526 of 5 stars$10.47-2.4%$19.33+84.7%-18.0%$627.09M$1.12B11.632,100News CoveragePositive NewsNVCRNovoCure3.6588 of 5 stars$17.80-1.1%$32.83+84.5%-0.7%$2.01B$605.22M0.001,488Analyst ForecastLMATLeMaitre Vascular2.476 of 5 stars$83.05+0.6%$97.83+17.8%-1.6%$1.87B$219.86M41.94490Positive NewsEYENational Vision2.5443 of 5 stars$23.01-0.7%$18.67-18.9%+88.3%$1.83B$1.82B64.3613,411Analyst ForecastENOVEnovis2.6225 of 5 stars$31.36-1.3%$58.00+84.9%-25.5%$1.82B$2.11B10.127,367Analyst ForecastCNMDCONMED4.4228 of 5 stars$52.10-0.1%$62.20+19.4%-24.4%$1.61B$1.31B12.083,900AORTArtivion2.6592 of 5 stars$31.17-0.1%$32.00+2.7%+18.3%$1.33B$388.54M124.761,600CDRECadre2.9797 of 5 stars$31.94-0.3%$37.50+17.4%-7.3%$1.30B$567.56M33.722,284TNDMTandem Diabetes Care4.1176 of 5 stars$18.64-1.6%$33.43+79.3%-65.5%$1.26B$940.20M-6.712,650Positive NewsAnalyst ForecastESTAEstablishment Labs1.5275 of 5 stars$42.71+4.3%$52.40+22.7%-1.6%$1.18B$166.02M0.001,018Analyst ForecastLQDALiquidia Technologies3.1557 of 5 stars$12.46-4.9%$26.89+115.8%+13.0%$1.12B$14M0.0050 Related Companies and Tools Related Companies NVCR Alternatives LMAT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives AORT Alternatives CDRE Alternatives TNDM Alternatives ESTA Alternatives LQDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
